Barely Significant
← all excerpts

A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils.

Heliyon · 2022 · PMC9218150 · PMID 35756113

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

showed a trendp = 0.05actually significant
An integrated analysis of approved benralizumab and mepolizumab doses showed a trend of 9% reduction in moderate-to-severe exacerbations (RR = 0.91, 95% CI [0.83, 1.00], p = 0.05, level of evidence C) ( Figure 2 A).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.